UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 16, 2019
YIELD10 BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
|
| | |
| 001-33133 | | 04-3158289 |
| (Commission File Number) | | (IRS Employer Identification No.) |
|
| | |
| 19 Presidential Way, Woburn, Massachusetts | | 01801 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(617) 583-1700
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act: |
| | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock | YTEN | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events
On August 19, 2019, Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the Company had expanded its non-exclusive research license with Bayer for soybean crop research to include a new discovery related to its C3004 yield trait gene. Under the amended research license, Bayer will have access to these new developments from Yield10's C3004 program and new advanced technology related to the C3004 trait and its potential to increase seed yield. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
|
| | | |
| (d) | Exhibits. |
| | |
| Exhibit No. | Description |
| | |
| Press Release of Yield10 Bioscience, Inc. dated August 19, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| |
| | | |
| | | YIELD10 BIOSCIENCE, INC. |
| | | |
| Date: August 19, 2019 | By: | /s/ Oliver Peoples |
| | | Oliver Peoples |
| | | President and Chief Executive Officer |
